• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 23
  • 7
  • 5
  • Tagged with
  • 35
  • 35
  • 31
  • 30
  • 29
  • 20
  • 18
  • 16
  • 15
  • 15
  • 11
  • 10
  • 10
  • 9
  • 8
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Relevanz von Depression und generalisierter Angststörung bei Patienten einer Brustschmerzambulanz: Ist ein Screening für eine Depression und eine generalisierte Angststörung in einer Brustschmerzambulanz sinnvoll?

Brandt, Michael 03 December 2018 (has links)
No description available.
2

Adhärenz bei oraler Capecitabin-Therapie - Zusammenhänge mit Angststörungen / Adherence to oral capecitabine therapy - Relation to anxiety disorders

Steimer, Ann-Kathrin January 2021 (has links) (PDF)
Laut Schätzungen des Robert Koch-Instituts erkranken jährlich fast 500.000 Personen an einer Krebserkrankung, mit steigender Tendenz. Durch stetige Fortschritte in der Forschung kam es durch die Entwicklung einer Chemotherapie in Tablettenform zu einem Paradigmenwechsel in der Krebstherapie. Für ein optimales Therapie-Outcome ist es von großer Bedeutung, dass die Patienten ein adhärentes Verhalten zeigen. Weiterhin zeigt sich in der bisherigen Literatur, dass psychische Komorbiditäten die Adhärenz und damit den Behandlungserfolg gleichermaßen beeinflussen können. Dies wurde in der vorliegenden Arbeit evaluiert. Die Studie umfasste insgesamt 69 Krebspatientinnen und -Patienten, die eine Chemotherapie mit Capecitabin erhielten. Untersucht wurden Gruppenunterschiede zwischen soziodemografischen und klinischen Variablen auf der einen Seite und Adhärenz auf der anderen Seite sowie die klinisch relevante Belastung durch Angstsymptome. Zur Datenerhebung wurden zum einen der MARS-Fragebogen zur Erfassung der Adhärenz und zum anderen der GAD-7 zur Erfassung der Angstsymptomatik verwendet. Adhärentes Verhalten in Bezug auf die Einnahme von Capecitabin zeigte sich bei 75.4% der Personen im untersuchten Studienkollektiv. Dieses Ergebnis steht in Einklang mit bisherigen Publikationen, die ebenfalls den Zusammenhang zwischen Adhärenz bei Capecitabin untersuchten. Die weitere Hypothese war, dass höhere Angstbelastungen unter Patienten signifikant mit einer verminderten Adhärenz in Zusammenhang stehen. Dies konnte in der vorliegenden Studie jedoch nicht festgestellt werden. Einerseits zeigte zwar nur ein geringer Anteil der untersuchten Patienten Hinweise einer Angststörung (7%), andererseits wurde festgestellt, dass nicht alle dieser Patienten eine psychotherapeutische Behandlung erhielten. Für zukünftige Forschungen wäre zu überlegen, weitere Messinstrumente zur Diagnostik einer niederschwelligen Angst einzusetzen. Weiterhin wären ein größeres Therapieangebot und umfassendere psychosoziale Unterstützung dringend erforderlich. Abschließend bleibt festzuhalten, dass in Zukunft weitere Studien, v.a. auch mit größeren Fallzahlen sowie Längsschnitt- oder Follow-up-Studien zu diesem Forschungsthema dringend indiziert sind. / According to estimates by The Robert Koch Institute, almost 500,000 people are diagnosed with cancer every year, and the numbers are rising. Steady progress in research has led to a paradigm shift in cancer therapy with the development of chemotherapy in tablet form. For an optimal therapy outcome, it is of great importance that patients show adherent behavior. Furthermore, previously published literature shows that psychological comorbidities can equally influence adherence and thus treatment success. This is what has been evaluated and is presented in this paper. The study included a total number of 69 cancer patients receiving chemotherapy with capecitabine. Group differences were investigated between sociodemographic and clinical variables as well as adherence and the clinically relevant impact of anxiety symptoms. For data collection, the MARS questionnaire was used to assess adherence and the GAD-7 to assess anxiety symptoms. Adherence to capecitabine was shown in 75.4% of individuals in the study population examined. This result is consistent with previous publications that also examined the relationship between adherence to capecitabine. A further hypothesis was that higher anxiety levels amongst patients are significantly associated with reduced adherence. However, this could not be established in the present study. Although only a small proportion of the patients studied showed evidence of an anxiety disorder (7%), it was found that not all of these patients received psychotherapeutic treatment. For future research, it would be worth considering the use of additional measurement instruments for the diagnosis of low-threshold anxiety. Furthermore, a more extensive range of therapies and more comprehensive psychosocial support are urgently needed. In conclusion, further studies on this research topic should be conducted, particularly with a greater number of cases as well as longitudinal or follow-up studies.
3

Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication

Kessler, Ronald C., Brandenburg, Nancy, Lane, Michael, Roy-Byrne, Peter, Stang, Paul D., Stein, Dan J., Wittchen, Hans-Ulrich 29 January 2013 (has links) (PDF)
Background. The proposed revisions of the ICD and DSM diagnostic systems have led to increased interest in evaluation of diagnostic criteria. This report focuses on the DSM-IV requirement that episodes of generalized anxiety disorder (GAD) must persist for at least 6 months. Community epidemiological data are used to study the implications of changing this requirement in the range 1–12 months for estimates of prevalence, onset, course, impairment, co-morbidity, associations with parental GAD, and sociodemographic correlates. Method. Data come from the US National Comorbidity Survey Replication (NCS-R), a US household survey carried out during 2001–2003. Version 3.0 of the WHO Composite International Diagnostic Interview (WMH-CIDI) was used to assess DSM-IV anxiety disorders, mood disorders, substance disorders, and impulse-control disorders. Results. Lifetime, 12-month, and 30-day prevalence estimates of DSM-IV GAD changed from 6·1%, 2·9%, and 1·8% to 4·2–12·7%, 2·2–5·5%, and 1·6–2·6% when the duration requirement was changed from 6 months to 1–12 months. Cases with episodes of 1–5 months did not differ greatly from those with episodes of [gt-or-equal, slanted]6 months in onset, persistence, impairment, co-morbidity, parental GAD, or sociodemographic correlates. Conclusions. A large number of people suffer from a GAD-like syndrome with episodes of <6 months duration. Little basis for excluding these people from a diagnosis is found in the associations examined here.
4

Epidemiologie und nosologischer Status der Generalisierten Angststörung / Prevalence and nosological status of generalized anxiety disorder

Hoyer, Jürgen, Beesdo, Katja, Becker, Eni S., Wittchen, Hans-Ulrich 09 October 2012 (has links) (PDF)
Theoretischer Hintergrund: Die diagnostischen Kriterien der Generalisierten Angststörung (GAS) und ihr Status als eigenständige psychische Störung waren lange umstritten. Inzwischen liegen neuere epidemiologische Daten vor, die ein präziseres Bild dieser Störung und ihrer Besonderheiten ermöglichen. Methode: Es wird ein systematischer Überblick zu Prävalenz, Verlauf und Komorbidität, zur Beeinträchtigung und zum Inanspruchnahmeverhalten sowie zur Spezifität des Kernsymptoms (Sorgen) erstellt. Ergebnisse: GAS ist eine häufige Störung, die im jungen Erwachsenenalter einsetzt, jedoch auch – anders als andere Angststörungen – hohe Inzidenzraten im mittleren Lebensalter aufweist. Der Verlauf ist eher chronisch. Trotz hoher Komorbidität lässt sich die Störung valide abgrenzen. Klinisch relevante Sorgen erweisen sich als störungsspezifisch. Die Beeinträchtigungen sind auch bei GAS-Patienten ohne Komorbidität beträchtlich. Schlussfolgerung: Der Forschungsstand spricht für die Bedeutung und Eigenständigkeit der Diagnose sowie für die stärkere Beachtung offener Forschungsfragen. / Background: The diagnostic criteria for generalized anxiety disorder (GAD) and its status as an independent mental disorder have been controversial. More recent epidemiological data provide a more precise picture of this disorder and its specific features. Methods: A systematic overview is given in regard to prevalence, course and comorbidity, impairment, and help-seeking behavior as well as to specificity of the core symptom (worries). Results: GAD is a frequent disorder with high incidence rates in middle-age groups, which are not seen in other anxiety disorders. Despite the high comorbidity GAD can be validly distinguished. Clinically relevant worries have been proven as specific for the disorder. The impairments are also considerable for patients without comorbid disorders. Conclusions: Research supports the independent status of GAD and the importance of this diagnosis. Unsolved questions are to be analyzed in future research.
5

Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms

Bollu, Vamsi, Bushmakin, Andrew G., Cappelleri, Joseph C., Chen, Chwen-Cheng, Feltner, Douglas, Wittchen, Hans-Ulrich 03 December 2012 (has links) (PDF)
Background and Objectives: To characterize the impact of pregabalin on sleep in patients with generalized anxiety disorder (GAD) and to determine whether the impact is a direct or an indirect effect, mediated through the reduction of anxiety symptoms. Methods: A post-hoc analysis of data from a randomized, double-blind, placebo- and active-controlled study in patients with GAD was conducted. Patients received pregabalin 300 mg/day, venlafaxine XR 75 mg/day or placebo for a week, followed by pregabalin 300-600 mg/day, venlafaxine XR 75-225 mg/day, or placebo for 7 weeks. Treatment effect on sleep was evaluated using the Medical Outcomes Study Sleep Scale. Anxiety symptoms were assessed with the Hamilton Anxiety Rating Scale. A mediation model was used to estimate separately for both treatment arms the direct and indirect treatment effects on sleep disturbance. Results: Compared with placebo (n = 128), treatment with pregabalin (n = 121) significantly reduced scores on the sleep disturbance subscale and Sleep Problems Index II at both week 4 and week 8, and the sleep adequacy subscale at week 8. Venlafaxine XR (n = 125) had no significant effect on these measures. The mediation model indicated that 53% of the total pregabalin effect on sleep disturbance was direct (p < 0.01) and 47% indirect, mediated through anxiety symptoms (p < 0.05). Conclusions: Pregabalin decreased sleep disturbance in patients with GAD both directly, and indirectly by reducing anxiety symptoms. Given the drug specificity of the results, this study provides evidence of an additional important pathway of action for pregabalin and its efficacy in GAD.
6

Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms

Bollu, Vamsi, Bushmakin, Andrew G., Cappelleri, Joseph C., Chen, Chwen-Cheng, Feltner, Douglas, Wittchen, Hans-Ulrich January 2010 (has links)
Background and Objectives: To characterize the impact of pregabalin on sleep in patients with generalized anxiety disorder (GAD) and to determine whether the impact is a direct or an indirect effect, mediated through the reduction of anxiety symptoms. Methods: A post-hoc analysis of data from a randomized, double-blind, placebo- and active-controlled study in patients with GAD was conducted. Patients received pregabalin 300 mg/day, venlafaxine XR 75 mg/day or placebo for a week, followed by pregabalin 300-600 mg/day, venlafaxine XR 75-225 mg/day, or placebo for 7 weeks. Treatment effect on sleep was evaluated using the Medical Outcomes Study Sleep Scale. Anxiety symptoms were assessed with the Hamilton Anxiety Rating Scale. A mediation model was used to estimate separately for both treatment arms the direct and indirect treatment effects on sleep disturbance. Results: Compared with placebo (n = 128), treatment with pregabalin (n = 121) significantly reduced scores on the sleep disturbance subscale and Sleep Problems Index II at both week 4 and week 8, and the sleep adequacy subscale at week 8. Venlafaxine XR (n = 125) had no significant effect on these measures. The mediation model indicated that 53% of the total pregabalin effect on sleep disturbance was direct (p < 0.01) and 47% indirect, mediated through anxiety symptoms (p < 0.05). Conclusions: Pregabalin decreased sleep disturbance in patients with GAD both directly, and indirectly by reducing anxiety symptoms. Given the drug specificity of the results, this study provides evidence of an additional important pathway of action for pregabalin and its efficacy in GAD.
7

Patterns of healthcare utilization in patients with generalized anxiety disorder in general practice in Germany

Berger, Ariel, Dukes, Ellen, Wittchen, Hans-Ulrich, Morlock, Robert, Edelsberg, John, Oster, Gerry 03 December 2012 (has links) (PDF)
Background and Objectives: To describe patterns of healthcare utilization among patients with generalized anxiety disorder (GAD) in general practitioner (GP) settings in Germany. Methods: Using a large computerized database with information from GP practices across Germany, we identified all patients, aged > 18 years, with diagnoses of, or prescriptions for, GAD (ICD-10 diagnosis code F41.1) between October 1, 2003 and September 30, 2004 ("GAD patients"). We also constituted an age- and sex-matched comparison group, consisting of randomly selected patients without any GP encounters or prescriptions for anxiety or depression (a common comorbidity in GAD) during the same period. GAD patients were then compared to those in the matched comparison group over the one-year study period. Results: The study sample consisted of 3340 GAD patients and an equal number of matched comparators. Mean age was 53.2 years; 66.3% were women. Over the 12-month study period, GAD patients were more likely than matched comparators to have encounters for various comorbidities, including sleep disorders (odds ratio [OR] = 6.75 [95% CI = 5.31, 8.57]), substance abuse disorders (3.91 [2.89, 5.28]), and digestive system disorders (2.62 [2.36, 2.91]) (all p < 0.01). GAD patients averaged 5.6 more GP encounters (10.5 [SD = 8.8] vs 4.9 [5.7] for comparison group) and 1.4 more specialist referrals (2.3 [2.9] vs 0.9 [1.7]) (both p < 0.01). Only 58.3% of GAD patients received some type of psychotropic medication (i.e., benzodiazepines, antidepressants, and/or sedatives/hypnotics). Conclusions: Patients with GAD in GP practices in Germany have more clinically recognized comorbidities and higher levels of healthcare utilization than patients without anxiety or depression.
8

Establishing non-inferiority in treatment trials in psychiatry - guidelines from an Expert Consensus Meeting

Nutt, David, Allgulander, Christer, Lecrubier, Yves, Peters, T., Wittchen, Hans-Ulrich 26 February 2013 (has links) (PDF)
Comparing the efficacy of different treatments in psychiatry is difficult for many reasons, even when they are investigated in `head-to-head' studies. A consensus meeting was, therefore, held to produce best practice guidelines for such studies. This article presents the conclusions of this consensus and illustrates it using published data in the field of antidepressant treatment of generalized anxiety disorder.
9

Broadening the definition of generalized anxiety disorder: Effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication

Ruscio, Ayelet Meron, Chiu, Wai Tat, Roy-Byrne, Peter, Stang, Paul E., Stein, Dan J., Wittchen, Hans-Ulrich, Kessler, Ronald C. 11 April 2013 (has links) (PDF)
Concerns have been raised that the DSM-IV requirements of 6-month duration, excessive worry, and three associated symptoms exclude a substantial number of people with clinically significant anxiety from a diagnosis of generalized anxiety disorder (GAD). We examined the implications of relaxing these three criteria for the estimated prevalence and predictive validity of GAD using nationally representative data from the US National Comorbidity Survey Replication. Relaxing all three criteria more than doubles the estimated prevalence of GAD. Broadly defined GAD significantly predicts the subsequent first onset of a wide range of temporally secondary disorders. The odds of secondary disorders are somewhat smaller for broadly defined than DSM-IV GAD, though few of these differences are statistically significant. Results suggest that subthreshold manifestations of GAD are significantly related to elevated risk of subsequent psychopathology. Further research is needed to determine whether broadening the current diagnostic criteria results in a more valid characterization of GAD.
10

Association between generalized anxiety levels and pain in a community sample: Evidence for diagnostic specificity

Beesdo, Katja, Hoyer, Jürgen, Jacobi, Frank, Low, Nancy C.P., Höfler, Michael, Wittchen , Hans-Ulrich 13 April 2013 (has links) (PDF)
Background: It is unclear whether generalized anxiety disorder (GAD) has a specific relationship to pain syndromes, going beyond the established association of pain with anxiety syndromes in general. Methods: Mental disorders were assessed in a community sample (N = 4181; 18–65 years) using the DSM-IV/M-CIDI. Several threshold definitions were used to define GAD and medically unexplained pain. Results: The association between pain and GAD (odds ratio, OR = 5.8 pain symptoms; OR = 16.0 pain disorder) is stronger than the association between pain and other anxiety disorders (OR = 2.4 pain symptoms; OR = 4.0 pain disorder). This association extends to subthreshold level definitions of GAD with some indication for a non-linear dose–response relationship. The GAD-pain link cannot sufficiently be explained by demographic factors, comorbid mental or physical disorders. Conclusions: The association of pain and generalized anxiety is not artifactual. Compared to other anxiety syndromes, it appears to be stronger and more specific suggesting the need to explore clinical and public health implications.

Page generated in 0.0778 seconds